This research aims to uncover the therapeutic potential of luteolin in targeting specific pathways in ER+ breast cancer stem cells.
Network pharmacology analysis to identify targets
Evaluation of luteolin's effects on CDK1/Cyclin B
In vitro studies on breast cancer stem cells
Luteolin demonstrated significant inhibition of CDK1/Cyclin B
Support for luteolin's clinical development as a therapeutic agent
Identification of novel molecular targets in breast cancer stem cells
Abstract
LT from VN shows promise as a therapeutic agent targeting CDK1/Cyclin B in ER+ breast cancer stem cells, supporting its potential for clinical development.